Cargando…
T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
BACKGROUND: D1 receptors, which couple to inhibitory G-proteins, have been shown to regulate neuronal growth and development, mediate some behavioral responses. Its function has been shown to be altered in both neurologic and psychiatric disorders. To date, there is a lack of agonist PET tracers for...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888516/ http://dx.doi.org/10.1093/schbul/sby016.432 |
_version_ | 1783312540719120384 |
---|---|
author | Tamagnan, Gilles Barret, Olivier Alagille, David Carroll, Vincent Madonia, Jennifer Constantinescu, Cristian SanDiego, Christine Papin, Caroline Morley, Thomas Russell, David McCarthy, Timothy Zhang, Lei Gray, David Villalobos, Anna Lee, Chewah Chen, Jianqing Seibyl, John Marek, Kenneth |
author_facet | Tamagnan, Gilles Barret, Olivier Alagille, David Carroll, Vincent Madonia, Jennifer Constantinescu, Cristian SanDiego, Christine Papin, Caroline Morley, Thomas Russell, David McCarthy, Timothy Zhang, Lei Gray, David Villalobos, Anna Lee, Chewah Chen, Jianqing Seibyl, John Marek, Kenneth |
author_sort | Tamagnan, Gilles |
collection | PubMed |
description | BACKGROUND: D1 receptors, which couple to inhibitory G-proteins, have been shown to regulate neuronal growth and development, mediate some behavioral responses. Its function has been shown to be altered in both neurologic and psychiatric disorders. To date, there is a lack of agonist PET tracers for the D1 receptors labeled with 18F with relevance in clinical studies. We report the evaluation in non-human primates of [18F]MNI-968 (PF-06730110), a novel PET radiotracer of the D1 receptors METHODS: Four brain PET studies, 2 baselines and 2 blockade studies using PF-2562, a D1 partial agonist compound, were conducted for 90 min in two rhesus monkeys with [18F]MNI-968 (169 ± 31 MBq). [18F]PF-06730110 was administered at the same dose level for both monkeys as a bolus followed by a 2-hour infusion, with [18F]MNI-968 administered 30 min into the infusion. Additionally, six brain PET studies were conducted over 180 min (317 ± 49 MBq) in 6 healthy human volunteers (3 test/retest and 3 test). PET data were modeled with 2-tissue compartmental model (2T), Logan graphical analysis (LGA), and non-invasive Logan graphical analysis (NI-LGA) with cerebellar cortex as reference region to estimate total distribution volume VT, and binding potential BPND. For the blockade studies in rhesus monkeys, occupancy was estimated from BPND at baseline and post blockade. RESULTS: In rhesus monkeys, [18F]MNI-968 (PF-06730110), penetrated the brain with a peak whole-brain uptake up to ~3% of the injected dose at ~ 6 min post injection and showed a fast washout. The highest signal was found in the caudate, putamen, with moderate extrastriatal uptake. The lowest signal was in the cerebellum. BPND values were up to ~1.4 in the putamen. All three quantification methods (2T, LGA and NI-LGA) were in excellent agreement, with a similar estimated D1 receptors occupancy of PF-06730110 of ~40% for both monkeys in the caudate and putamen. In human, [18F]MNI-968 kinetics appeared to be faster compared to non-human primates, with a BPND in the putamen of ~0.8. Initial measurement of test-retest reproducibility was ≤ 7% for BPND in the striatal regions. DISCUSSION: Our work showed that [18F]MNI-968 ([18F]PF-06730110), is a promising agonist PET radiotracer for imaging D1agnist receptors that can be quantified non-invasively. Studies are currently ongoing both in non-human and human primates to further characterize the tracer. |
format | Online Article Text |
id | pubmed-5888516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58885162018-04-11 T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN Tamagnan, Gilles Barret, Olivier Alagille, David Carroll, Vincent Madonia, Jennifer Constantinescu, Cristian SanDiego, Christine Papin, Caroline Morley, Thomas Russell, David McCarthy, Timothy Zhang, Lei Gray, David Villalobos, Anna Lee, Chewah Chen, Jianqing Seibyl, John Marek, Kenneth Schizophr Bull Abstracts BACKGROUND: D1 receptors, which couple to inhibitory G-proteins, have been shown to regulate neuronal growth and development, mediate some behavioral responses. Its function has been shown to be altered in both neurologic and psychiatric disorders. To date, there is a lack of agonist PET tracers for the D1 receptors labeled with 18F with relevance in clinical studies. We report the evaluation in non-human primates of [18F]MNI-968 (PF-06730110), a novel PET radiotracer of the D1 receptors METHODS: Four brain PET studies, 2 baselines and 2 blockade studies using PF-2562, a D1 partial agonist compound, were conducted for 90 min in two rhesus monkeys with [18F]MNI-968 (169 ± 31 MBq). [18F]PF-06730110 was administered at the same dose level for both monkeys as a bolus followed by a 2-hour infusion, with [18F]MNI-968 administered 30 min into the infusion. Additionally, six brain PET studies were conducted over 180 min (317 ± 49 MBq) in 6 healthy human volunteers (3 test/retest and 3 test). PET data were modeled with 2-tissue compartmental model (2T), Logan graphical analysis (LGA), and non-invasive Logan graphical analysis (NI-LGA) with cerebellar cortex as reference region to estimate total distribution volume VT, and binding potential BPND. For the blockade studies in rhesus monkeys, occupancy was estimated from BPND at baseline and post blockade. RESULTS: In rhesus monkeys, [18F]MNI-968 (PF-06730110), penetrated the brain with a peak whole-brain uptake up to ~3% of the injected dose at ~ 6 min post injection and showed a fast washout. The highest signal was found in the caudate, putamen, with moderate extrastriatal uptake. The lowest signal was in the cerebellum. BPND values were up to ~1.4 in the putamen. All three quantification methods (2T, LGA and NI-LGA) were in excellent agreement, with a similar estimated D1 receptors occupancy of PF-06730110 of ~40% for both monkeys in the caudate and putamen. In human, [18F]MNI-968 kinetics appeared to be faster compared to non-human primates, with a BPND in the putamen of ~0.8. Initial measurement of test-retest reproducibility was ≤ 7% for BPND in the striatal regions. DISCUSSION: Our work showed that [18F]MNI-968 ([18F]PF-06730110), is a promising agonist PET radiotracer for imaging D1agnist receptors that can be quantified non-invasively. Studies are currently ongoing both in non-human and human primates to further characterize the tracer. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888516/ http://dx.doi.org/10.1093/schbul/sby016.432 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Tamagnan, Gilles Barret, Olivier Alagille, David Carroll, Vincent Madonia, Jennifer Constantinescu, Cristian SanDiego, Christine Papin, Caroline Morley, Thomas Russell, David McCarthy, Timothy Zhang, Lei Gray, David Villalobos, Anna Lee, Chewah Chen, Jianqing Seibyl, John Marek, Kenneth T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN |
title | T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN |
title_full | T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN |
title_fullStr | T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN |
title_full_unstemmed | T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN |
title_short | T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN |
title_sort | t156. in vivo characterization of the first agonist dopamine d1 receptors pet imaging tracer [18f]mni-968 in human |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888516/ http://dx.doi.org/10.1093/schbul/sby016.432 |
work_keys_str_mv | AT tamagnangilles t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT barretolivier t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT alagilledavid t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT carrollvincent t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT madoniajennifer t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT constantinescucristian t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT sandiegochristine t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT papincaroline t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT morleythomas t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT russelldavid t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT mccarthytimothy t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT zhanglei t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT graydavid t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT villalobosanna t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT leechewah t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT chenjianqing t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT seibyljohn t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman AT marekkenneth t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman |